Last reviewed · How we verify
NCT03246438
Choice Architecture and Colorectal Cancer Screening Outreach
NA trial testing Colonoscopy only in Cancer of Colon in 423 participants. Completed in 14 July 2018.
14 March 2018
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 423 |
| Start date | 14 November 2017 |
| Primary completion | 14 March 2018 |
| Estimated completion | 14 July 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Colonoscopy only
- Colonoscopy outreach + mailed FIT follow-up
- Colonoscopy + Mailed FIT outreach and follow-up
Conditions studied
- Cancer of Colon — all drugs for Cancer of Colon →
Sponsor
University of Pennsylvania
Who can join
Adults 50 to 74, any sex, with Cancer of Colon. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot study is a 3-arm randomized control trial assessing the effectiveness of sequential or active choice in CRC (colorectal cancer) screening outreach vs. colonoscopy outreach only, in patients between 50-74 years old, who have received care at the University City or Valley Forge CCA (Community Care Associates) practices, are due for screening, and are asymptomatic for CRC. The three arms are: Arm 1: Direct schedule colonoscopy (Control), Arm 2: Direct schedule colonoscopy followed by mailed FIT(Fecal Immunochemical Test) (Sequential Choice), and Arm 3: Choice of direct schedule colonoscopy or mailed FIT (Active Choice).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Sequential or Active Choice for Colorectal Cancer Screening Outreach: A Randomized Clinical Trial.
Mehta SJ, Induru V, Santos D, Reitz C, et al · · 2019 · cited 16× · PMID 31469393 · DOI 10.1001/jamanetworkopen.2019.10305
Verify or expand the search:
- PubMed search for NCT03246438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Colon
Currently open trials in the same condition.
- NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
- NCT05179824 — Tempus Priority Study: A Pan-tumor Observational Study · active not recruiting
- NCT04259398 — Anesthesia and Cancer Study: Colon Cancer · NA · active not recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03246438 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 20 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03246438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing